was read the article
array:22 [ "pii" => "S1665268124003053" "issn" => "16652681" "doi" => "10.1016/j.aohep.2024.101511" "estado" => "S300" "fechaPublicacion" => "2024-07-01" "aid" => "101511" "copyrightAnyo" => "2024" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Ann Hepatol. 2024;29:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S1665268124002680" "issn" => "16652681" "doi" => "10.1016/j.aohep.2024.101474" "estado" => "S300" "fechaPublicacion" => "2024-07-01" "aid" => "101474" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Ann Hepatol. 2024;29:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Impact of preoperative nonselective beta-blocker use on acute kidney injury after living donor liver transplantation: Propensity score analysis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Hye-Won Jeong, Jae Hwan Kim, Sang-bin Han, Hye-Mee Kwon, In-Gu Jun, Jun-Gol Song, Gyu-Sam Hwang" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Hye-Won" "apellidos" => "Jeong" ] 1 => array:2 [ "nombre" => "Jae Hwan" "apellidos" => "Kim" ] 2 => array:2 [ "nombre" => "Sang-bin" "apellidos" => "Han" ] 3 => array:2 [ "nombre" => "Hye-Mee" "apellidos" => "Kwon" ] 4 => array:2 [ "nombre" => "In-Gu" "apellidos" => "Jun" ] 5 => array:2 [ "nombre" => "Jun-Gol" "apellidos" => "Song" ] 6 => array:2 [ "nombre" => "Gyu-Sam" "apellidos" => "Hwang" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268124002680?idApp=UINPBA00004N" "url" => "/16652681/0000002900000004/v1_202406280659/S1665268124002680/v1_202406280659/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S1665268124003041" "issn" => "16652681" "doi" => "10.1016/j.aohep.2024.101510" "estado" => "S300" "fechaPublicacion" => "2024-07-01" "aid" => "101510" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Ann Hepatol. 2024;29:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Outcomes and risk factors for mortality in <span class="elsevierStyleItalic">clostridioides difficile</span> infection in patients with NAFLD and NASH" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0001" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1948 "Ancho" => 2670 "Tamanyo" => 300444 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0001" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spara001" class="elsevierStyleSimplePara elsevierViewall">Diagram for study sample selection.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ankoor H. Patel, Gaurav N. Pathak, Alexander Chen, Patricia Greenberg, Natale Mazzaferro, Anish Patel, Naveen Mallangada, Carlos D. Minacapelli, Kaitlyn Catalano, Hansel Suthar, Vinod K. Rustgi" "autores" => array:11 [ 0 => array:2 [ "nombre" => "Ankoor H." "apellidos" => "Patel" ] 1 => array:2 [ "nombre" => "Gaurav N." "apellidos" => "Pathak" ] 2 => array:2 [ "nombre" => "Alexander" "apellidos" => "Chen" ] 3 => array:2 [ "nombre" => "Patricia" "apellidos" => "Greenberg" ] 4 => array:2 [ "nombre" => "Natale" "apellidos" => "Mazzaferro" ] 5 => array:2 [ "nombre" => "Anish" "apellidos" => "Patel" ] 6 => array:2 [ "nombre" => "Naveen" "apellidos" => "Mallangada" ] 7 => array:2 [ "nombre" => "Carlos D." "apellidos" => "Minacapelli" ] 8 => array:2 [ "nombre" => "Kaitlyn" "apellidos" => "Catalano" ] 9 => array:2 [ "nombre" => "Hansel" "apellidos" => "Suthar" ] 10 => array:2 [ "nombre" => "Vinod K." "apellidos" => "Rustgi" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268124003041?idApp=UINPBA00004N" "url" => "/16652681/0000002900000004/v1_202406280659/S1665268124003041/v1_202406280659/en/main.assets" ] "en" => array:17 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis" "tieneTextoCompleto" => true "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Luis Vega, Daniela Simian, Abraham I. Gajardo, Marcelo Salinas, Andrea Urra, Máximo Cattaneo, Rosario Pino, Juan P. Roblero, Álvaro Urzúa, Katherine Rojas, Jaime Poniachik" "autores" => array:11 [ 0 => array:3 [ "nombre" => "Luis" "apellidos" => "Vega" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] ] ] 1 => array:3 [ "nombre" => "Daniela" "apellidos" => "Simian" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] ] ] 2 => array:3 [ "nombre" => "Abraham I." "apellidos" => "Gajardo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0002" ] ] ] 3 => array:3 [ "nombre" => "Marcelo" "apellidos" => "Salinas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] ] ] 4 => array:3 [ "nombre" => "Andrea" "apellidos" => "Urra" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] ] ] 5 => array:3 [ "nombre" => "Máximo" "apellidos" => "Cattaneo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] ] ] 6 => array:3 [ "nombre" => "Rosario" "apellidos" => "Pino" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] ] ] 7 => array:3 [ "nombre" => "Juan P." "apellidos" => "Roblero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] ] ] 8 => array:3 [ "nombre" => "Álvaro" "apellidos" => "Urzúa" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] ] ] 9 => array:3 [ "nombre" => "Katherine" "apellidos" => "Rojas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] ] ] 10 => array:4 [ "nombre" => "Jaime" "apellidos" => "Poniachik" "email" => array:1 [ 0 => "jaime_poniachik@yahoo.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0001" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Gastroenterology Section, Medicine Department, Hospital Clínico Universidad de Chile, Santiago, Chile" "etiqueta" => "a" "identificador" => "aff0001" ] 1 => array:3 [ "entidad" => "Critical Patient Care Unit, Medicine Department, Hospital Clínico Universidad de Chile, Santiago, Chile" "etiqueta" => "b" "identificador" => "aff0002" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0001" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0001" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1900 "Ancho" => 2167 "Tamanyo" => 152538 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0001" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spara001" class="elsevierStyleSimplePara elsevierViewall">Relationship between the number of coronary arteries with significant stenosis and the presence of hepatic fibrosis.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0001" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">1</span><span class="elsevierStyleSectionTitle" id="cesectitle0008">Introduction</span><p id="para0005" class="elsevierStylePara elsevierViewall">Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease worldwide, with an estimated prevalence of 25%. There are regional and ethnic differences, such as an estimated 31% prevalence in South America [<a class="elsevierStyleCrossRef" href="#bib0001">1</a>]. In Chile, data from 2009 showed a prevalence of 23% in the general population, which is estimated to be increasing [<a class="elsevierStyleCrossRef" href="#bib0002">2</a>]. The high prevalence of MASLD is strongly associated with metabolic syndrome and the increase in the rate of obesity. Chile is currently the country with the highest obesity rate, reaching 34.4% of the population aged over 15 years [<a class="elsevierStyleCrossRef" href="#bib0003">3</a>].</p><p id="para0006" class="elsevierStylePara elsevierViewall">Patients with MASLD have been shown to have an increased 10-year risk of cardiovascular events compared with healthy individuals. Cardiovascular disease is the leading cause of death in patients with non-alcoholic fatty liver disease (NAFLD) [<a class="elsevierStyleCrossRef" href="#bib0004">4</a>]. Moreover, patients in advanced stages of NAFLD and with liver fibrosis present with a higher rate of fatal and non-fatal cardiovascular complications, which are associated with the severity of fibrosis [<a class="elsevierStyleCrossRefs" href="#bib0005">5–7</a>]. Thus, the current literature recognizes the relationship between NAFLD and coronary heart disease (CHD) [<a class="elsevierStyleCrossRef" href="#bib0008">8</a>,<a class="elsevierStyleCrossRef" href="#bib0009">9</a>].</p><p id="para0007" class="elsevierStylePara elsevierViewall">Conversely, an increased risk of NAFLD has been reported in patients with CHD. Previous studies have shown a higher prevalence of NAFLD in patients with CHD, the frequency of which increased with the severity of CHD [<a class="elsevierStyleCrossRef" href="#bib0010">10</a>]. However, this “dose-response” between NAFLD and CHD severity was questioned in subsequent studies [<a class="elsevierStyleCrossRef" href="#bib0008">8</a>]. Moreover, evidence supporting NAFLD as a risk factor for CHD is scarce and controversial.</p><p id="para0008" class="elsevierStylePara elsevierViewall">This possible bidirectional relationship between NAFLD and CHD could be due to the common risk factors for both diseases. In a recent sub-analysis of the Framingham study, the presence of liver fibrosis was found to be associated with multiple cardiovascular risk factors, which could explain the higher cardiovascular mortality in patients with NAFLD [<a class="elsevierStyleCrossRef" href="#bib0009">9</a>]. Consequently, the current question in the literature is whether these cardiovascular risk factors are responsible for the association between NAFLD and CHD or whether liver fibrosis is an independent cardiovascular risk factor. The prevalence of liver fibrosis in patients with CHD is currently not known.</p><p id="para0009" class="elsevierStylePara elsevierViewall">This study aimed to determine the frequency of MASLD and liver fibrosis in patients with CHD and to assess whether significant coronary stenosis is associated with steatosis and liver fibrosis.</p></span><span id="sec0002" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2</span><span class="elsevierStyleSectionTitle" id="cesectitle0009">Material and methods</span><span id="sec0003" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2.1</span><span class="elsevierStyleSectionTitle" id="cesectitle0010">Design and study population</span><p id="para0010" class="elsevierStylePara elsevierViewall">This observational, cross-sectional study was conducted in adult patients who underwent coronary angiography for suspected coronary artery disease between July 2021 and July 2022 at the Hospital Clínico Universidad de Chile. Patients with an indication for coronary angiography for non-ischemic causes, pregnant women, patients with transaminases greater than or equal to five times the upper limit of normal, history of known chronic liver damage, personal history of cancer, abdominal surgery up to 3 months prior, and history of heart failure or cardiac hypodebit syndrome (defined as left ventricular ejection fraction <50%, as measured by transthoracic echocardiography or ventriculography) were excluded.</p></span><span id="sec0004" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2.2</span><span class="elsevierStyleSectionTitle" id="cesectitle0011">Clinical information, exposure and outcomes</span><p id="para0011" class="elsevierStylePara elsevierViewall">Patients who had undergone coronary angiography were telephonically invited to participate in the study and selected consecutively according to the inclusion and exclusion criteria during the study period.</p><p id="para0012" class="elsevierStylePara elsevierViewall">Trained personnel collected demographic data, clinical history, and laboratory test reports (closest within six months of the date of coronary angiography) from the clinical records using an established form. Coronary angiography revealed the number of vessels affected and the magnitude of the stenosis. Significant coronary heart disease is defined as the presence of > 50% stenosis in at least one coronary artery [<a class="elsevierStyleCrossRef" href="#bib0011">11</a>]. Hepatic steatosis and fibrosis were determined through liver elastography (Fibroscan® model 530 Compact 2018); it was performed up to 6 months after coronary angiography by an expert operator. According to previous evidence, hepatic steatosis was defined as the presence of > 5% hepatic fat (controlled attenuation parameter [CAP] > 237 dB/m) and significant fibrosis was determined at the liver stiffness measurement (LSM) of ≥ 6.5 kPa [<a class="elsevierStyleCrossRef" href="#bib0012">12</a>]. Alcohol consumption was considered as > 3 drinks/week in men and > 2 drinks/week in women.</p></span><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2.3</span><span class="elsevierStyleSectionTitle" id="cesectitle0012">Statistical analysis</span><p id="para0013" class="elsevierStylePara elsevierViewall">A sample size calculation was performed according to the literature-estimated prevalence of NAFLD of 31% [<a class="elsevierStyleCrossRef" href="#bib0001">1</a>], with a 95% confidence interval (CI) and a precision of 10%, resulting in 91 patients (considering a loss-adjusted sample of 10%).</p><p id="para0014" class="elsevierStylePara elsevierViewall">The normal distribution of continuous variables was assessed using the Shapiro–Wilk test. Descriptive statistics were expressed as frequency and percentage for categorical variables and as mean (standard deviation) or median (interquartile range [IQR]) for continuous variables, as considered appropriate. Bivariate analysis was performed using Student's <span class="elsevierStyleItalic">t</span>-test or Mann–Whitney U test, as considered appropriate (for continuous variables), and Fisher's exact test (for categorical variables).</p><p id="para0015" class="elsevierStylePara elsevierViewall">To test the association between significant coronary stenosis and hepatic fibrosis, we considered the exposure in two different manners: estimating its linear effect on the outcome by using the absolute number of vessels with significant CHD, and as a dichotomized variable by grouping the patients in a group with two or more vessels with significant CHD and other with one or less vessels with CHD. Thus, different logistic regression models were performed to evaluate the effect of significant CHD (independent variable) on hepatic fibrosis (dependent variable) adjusted by the effect of T2DM and obesity in separate models. For each variable included in the models, we calculated the odds ratio (OR) with its 95% confidence interval (CI) and p-values. All analyses were performed using Stata 14.0 (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX, StataCorp LP) software. p-value <0.05 was considered strong evidence against the null statistical hypothesis.</p></span><span id="sec0006" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">2.4</span><span class="elsevierStyleSectionTitle" id="cesectitle0013">Ethical statements</span><p id="para0016" class="elsevierStylePara elsevierViewall">Written informed consent was obtained from each patient included in the study, and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the Ethics Committee of Hospital Clínico Universidad de Chile, Santiago, Chile (No. 33/2021).</p></span></span><span id="sec0007" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3</span><span class="elsevierStyleSectionTitle" id="cesectitle0014">Results</span><span id="sec0008" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3.1</span><span class="elsevierStyleSectionTitle" id="cesectitle0015">Patient characteristics</span><p id="para0017" class="elsevierStylePara elsevierViewall">During the study period, 702 coronary angiographies were performed, of which 113 patients met the inclusion criteria, 81 (72%) of whom presented with significant CHD on coronary angiography. Of the patients without significant CHD (<span class="elsevierStyleItalic">n</span> = 32), 24 had normal coronary angiography with no lesions; the remaining eight patients had less than 50% stenosis in at least one artery. There were no differences between the latter two groups (normal coronary angiography vs. less than 50% stenosis) in terms of demographic variables (age, sex), clinical variables (hypertension or diabetes mellitus 2), anthropometry, or steatosis. None of the patients had fibrosis.</p><p id="para0018" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0001">Table 1</a> describes the baseline characteristics of the patients, highlighting a higher proportion of male patients with CHD than those without (83% vs. 59%, <span class="elsevierStyleItalic">p</span> = 0.008) and a greater presence of type 2 diabetes mellitus (T2DM) in the same group (43% vs. 22%, <span class="elsevierStyleItalic">p</span> = 0.034). Furthermore, T2DM increased the odds of having two or more vessels affected by CHD (OR = 3.1 [CI 95%: 1.4 - 6.9], p-value = 0.006. In addition, glutamic-oxaloacetic transaminase levels were higher in the CHD group than in the group without CHD (median, 35 U/L [IQR 14–176 U/L] vs. 27 U/L [IQR 17–59 U/L]; <span class="elsevierStyleItalic">p</span> = 0.021).</p><elsevierMultimedia ident="tbl0001"></elsevierMultimedia></span><span id="sec0009" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3.2</span><span class="elsevierStyleSectionTitle" id="cesectitle0016">Hepatic steatosis and fibrosis and their relationship with coronary heart disease</span><p id="para0019" class="elsevierStylePara elsevierViewall">The overall frequency of hepatic steatosis was 52%, with no significant difference between the groups with and without CHD (50.6% vs. 56.3%; <span class="elsevierStyleItalic">p</span> = 0.371). The frequency of hepatic fibrosis was 12% and was observed only in the CHD group (17.3% vs. 0%; <span class="elsevierStyleItalic">p</span> = 0.010). There was no significant difference in median liver stiffness between the groups with and without CHD (4.5 [2.8–37.9] vs 4.5 [2.5–6.1] kPa, <span class="elsevierStyleItalic">p</span> = 0.292) (<a class="elsevierStyleCrossRef" href="#tbl0002">Table 2</a>).</p><elsevierMultimedia ident="tbl0002"></elsevierMultimedia><p id="para0020" class="elsevierStylePara elsevierViewall">Patients with T2DM showed a higher frequency of liver fibrosis than those without (31% vs. 7%, <span class="elsevierStyleItalic">p</span> = 0.006).</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">3.3</span><span class="elsevierStyleSectionTitle" id="cesectitle0017">Hepatic fibrosis and the number of vessels with significant coronary heart disease</span><p id="para0021" class="elsevierStylePara elsevierViewall">A higher frequency of hepatic fibrosis was found in patients with a higher number of vessels with significant CHD (<a class="elsevierStyleCrossRef" href="#fig0001">Fig. 1</a>). Thus, the number of vessels involved increased the probability of hepatic fibrosis (OR, 1.79; 95% CI, 1.06–3.04; <span class="elsevierStyleItalic">p</span> = 0.029). When categorizing the variable into two or more affected vessels, an increased strength of association with liver fibrosis was observed (OR, 3.44; 95% CI, 1.07–11.08, <span class="elsevierStyleItalic">p</span> = 0.038). However, the statistical evidence for both associations decreased when controlled for the history of diabetes mellitus (<a class="elsevierStyleCrossRef" href="#tbl0003">Table 3</a>). In contrast, the number of coronary vessels affected, as linear effect or dichotomized in two or more affected vessels, remained as risk factors for hepatic fibrosis after control by obesity (<a class="elsevierStyleCrossRef" href="#tbl0003">Table 3</a>). There was no significant difference in the frequency of liver fibrosis between patients with and without a history of acute myocardial infarction (11% vs. 14%, <span class="elsevierStyleItalic">p</span> = 0.775).</p><elsevierMultimedia ident="fig0001"></elsevierMultimedia><elsevierMultimedia ident="tbl0003"></elsevierMultimedia></span></span><span id="sec0011" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">4</span><span class="elsevierStyleSectionTitle" id="cesectitle0018">Discussion</span><p id="para0022" class="elsevierStylePara elsevierViewall">In this cohort of adult patients who underwent coronary angiography for suspected coronary artery disease, a high frequency of global hepatic steatosis, measured by CAP (52%), was observed. In addition, an association between the number of vessels with CHD and the presence of hepatic fibrosis was also observed, with T2DM being a confounding factor in this relationship because it was associated with the number of vessels with CHD (the exposure) and hepatic fibrosis (the outcome).</p><p id="para0023" class="elsevierStylePara elsevierViewall">Our results on hepatic steatosis showed a prevalence higher than that reported in the literature. In local studies conducted more than a decade ago, a 23% prevalence of hepatic steatosis was reported [<a class="elsevierStyleCrossRef" href="#bib0002">2</a>]. However, recent international literature shows a 31% prevalence of this disease in South America [<a class="elsevierStyleCrossRef" href="#bib0013">13</a>]. This could be attributed to the known increase in obesity and metabolic syndrome in the general Chilean population in recent decades [<a class="elsevierStyleCrossRef" href="#bib0003">3</a>]. However, the prevalence of steatosis did not significantly differ between the groups with and without CHD (51% vs. 56%), possibly because of lack of differences in body mass index (BMI) or waist circumference between the groups. In contrast, liver fibrosis was observed in 17% of the patients who underwent coronary angiography, with 6.2% (5/81) having advanced fibrosis (F3–F4). Interestingly, fibrosis was only observed in the group of patients with CHD and was not found in those without CHD.</p><p id="para0024" class="elsevierStylePara elsevierViewall">Some studies have evaluated the impact of steatosis or fibrosis on cardiovascular disease with controversial results. Ciardullo published a study that included 2734 participants and reported an NAFLD prevalence of 48.6%, with a presence of liver fibrosis in 9.7% [<a class="elsevierStyleCrossRef" href="#bib0008">8</a>]. This study revealed that patients with cardiovascular disease (defined as a history of CHD, and/or stroke or transient ischemic attack) had a higher incidence of hepatic steatosis (59.6% vs. 47.1%, <span class="elsevierStyleItalic">p</span> = 0.013) but not fibrosis (12.9% vs. 9.3%, <span class="elsevierStyleItalic">p</span> = 0.123). Similar results were observed by Choi <span class="elsevierStyleItalic">et al</span>., who found a higher prevalence of NAFLD in patients with coronary stenosis, as evidenced by coronary angiography (78% vs. 51%) [<a class="elsevierStyleCrossRef" href="#bib0010">10</a>]. Conversely, in a meta-analysis evaluating the impact of liver disease on cardiovascular disease, Wen <span class="elsevierStyleItalic">et al</span>. observed that the incidence of cardiovascular disease in the NAFLD group was twice that in the control group (RR, 2.26; <span class="elsevierStyleItalic">p</span> < 0.01) [<a class="elsevierStyleCrossRef" href="#bib0014">14</a>].</p><p id="para0025" class="elsevierStylePara elsevierViewall">Multiple studies have attempted to evaluate whether hepatic fibrosis is an independent cardiovascular risk factor or if other factors interfere with this association. In our study, we observed that the number of compromised coronary vessels increased the probability of hepatic fibrosis; however, this association was nullified after controlling for T2DM (present in 43% of the patients with CHD). The above argument favors the difficulty in evaluating the causal relationship between CHD and hepatic steatosis, with or without the presence of fibrosis, owing to the multiple confounding factors that interfere with the relationship. Previous studies have described the factors associated with the presence of liver fibrosis in patients with CHD. In a recent sub-analysis of the Framingham study, which included 3276 participants, an overall prevalence of steatosis of 28.8% and fibrosis of 8.8% (defined as an LSM ≥ 8.2 Kpa) was observed.<span class="elsevierStyleSup">9</span> It was further observed that compared with the participants without fibrosis, those with hepatic fibrosis had a higher frequency of obesity (OR, 3.11), hepatic steatosis (OR, 3.66), metabolic syndrome (OR, 2.80), and T2DM (OR, 2.67), which remained significant after adjusting for CAP and BMI. In contrast, Ciardullo <span class="elsevierStyleItalic">et al</span>. did not observe an independent association between liver fibrosis or steatosis with cardiovascular disease and heart failure after adjusting the models for confounding variables, such as diabetes, smoking, and age [<a class="elsevierStyleCrossRef" href="#bib0008">8</a>].</p><p id="para0026" class="elsevierStylePara elsevierViewall">In our study, a higher frequency of patients with T2DM was observed in the group with liver fibrosis, and also in those with coronary artery disease, so that T2DM represents a confounding factor. However, it is important to take into consideration this subgroup of patients, since it has been proposed that patients with early stage liver fibrosis (F1) with associated T2DM have an increased risk of more severe liver disease (cirrhosis and hepatocarcinoma) or also called "rapid progressors" [<a class="elsevierStyleCrossRef" href="#bib0015">15</a>] Therefore, diabetes patients with CHD and fibrosis may have a more rapid progression of liver disease.</p><p id="para0027" class="elsevierStylePara elsevierViewall">A recent meta-analysis investigated the incidence of cardiovascular disease and mortality in patients with MAFLD. Ten cohort studies were included in this meta-analysis, and the incidence of cardiovascular disease in the MAFLD group was found to be more than twice that in the control group (RR, 2.26; <span class="elsevierStyleItalic">p</span> < 0.01). Furthermore, cardiovascular disease mortality was 1.57 times higher in the MAFLD group than in the control group (RR, 1.57; <span class="elsevierStyleItalic">p</span> < 0.01) [<a class="elsevierStyleCrossRef" href="#bib0014">14</a>]. Although our study did not find a higher frequency of hepatic steatosis and MASLD in patients with altered coronary angiography findings, their association with hepatic fibrosis may be related to the results of this meta-analysis.</p><span id="sec0012" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">4.1</span><span class="elsevierStyleSectionTitle" id="cesectitle0019">Limitations</span><p id="para0028" class="elsevierStylePara elsevierViewall">The observational and cross-sectional design of this study limits the establishment of a causal relationship between CHD and liver fibrosis. In addition, the number of patients with liver fibrosis in this study was small, which prevented us from controlling for additional confounding factors that would have been possible with a larger sample size. However, the evaluation of steatosis and hepatic fibrosis was performed in the months following coronary angiography, a time during which patients could have made lifestyle changes, considering the recent diagnosis of CHD, thereby impacting their levels of hepatic steatosis. Also, the evaluation of hepatic steatosis and fibrosis was not performed through liver biopsy, considered the gold standard; transitional liver elastography (Fibroscan®), however, has a high diagnostic yield compared with liver biopsy. Finally, it is important to mention that we performed an objective assessment of coronary artery disease using coronary angiography rather than the noninvasive methods used in other studies, such as cardiovascular risk factors, which in turn allowed us to have a well-established control group. Thus, our research is one among the few investigations worldwide that have studied the presence of hepatic steatosis and the degree of associated fibrosis, specifically in the population with proven coronary artery disease, using validated clinical diagnostic methods.</p></span></span><span id="sec0013" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleLabel">5</span><span class="elsevierStyleSectionTitle" id="cesectitle0020">Conclusions</span><p id="para0029" class="elsevierStylePara elsevierViewall">MASLD is highly prevalent in patients with significant CHD without a history of known liver damage. Although the presence of confounding variables, especially T2DM, should be evaluated in future studies. These data suggest the need for a targeted search for MAFLD and liver fibrosis in patients with CHD, especially in those with T2DM.</p></span><span id="sec0014" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0021">Funding</span><p id="para0030" class="elsevierStylePara elsevierViewall">This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0022">Author contributions</span><p id="para0031" class="elsevierStylePara elsevierViewall">Participant enrollment: Luis Vega, Daniela Simian, Marcelo Salinas, Andrea Urra, Rosario Pino, Katherine Rojas. Data collection: Luis Vega, Daniela Simian, Marcelo Salinas, Andrea Urra. Statistical analysis: Abraham I. Gajardo, Daniela Simian. Results discussion: Luis Vega, Daniela Simian, Abraham I. Gajardo, Máximo Cattaneo, Juan P. Roblero, Álvaro Urzúa, Jaime Poniachik. Manuscript preparation: Luis Vega, Daniela Simian, Jaime Poniachik. Manuscript review and final approval: Luis Vega, Daniela Simian, Abraham I. Gajardo, Marcelo Salinas, Andrea Urra, Máximo Cattaneo, Rosario Pino, Juan P. Roblero, Álvaro Urzúa, Katherine Rojas, Jaime Poniachik. Jaime Poniachik is responsible for the integrity of the work as a whole.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:3 [ "identificador" => "xres2173883" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abss0001" "titulo" => "Introduction and Objectives" ] 1 => array:2 [ "identificador" => "abss0002" "titulo" => "Patients and Methods" ] 2 => array:2 [ "identificador" => "abss0003" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abss0004" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1842338" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xpalclavsec1842339" "titulo" => "Abbreviations" ] 3 => array:2 [ "identificador" => "sec0001" "titulo" => "Introduction" ] 4 => array:3 [ "identificador" => "sec0002" "titulo" => "Material and methods" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0003" "titulo" => "Design and study population" ] 1 => array:2 [ "identificador" => "sec0004" "titulo" => "Clinical information, exposure and outcomes" ] 2 => array:2 [ "identificador" => "sec0005" "titulo" => "Statistical analysis" ] 3 => array:2 [ "identificador" => "sec0006" "titulo" => "Ethical statements" ] ] ] 5 => array:3 [ "identificador" => "sec0007" "titulo" => "Results" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0008" "titulo" => "Patient characteristics" ] 1 => array:2 [ "identificador" => "sec0009" "titulo" => "Hepatic steatosis and fibrosis and their relationship with coronary heart disease" ] 2 => array:2 [ "identificador" => "sec0010" "titulo" => "Hepatic fibrosis and the number of vessels with significant coronary heart disease" ] ] ] 6 => array:3 [ "identificador" => "sec0011" "titulo" => "Discussion" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0012" "titulo" => "Limitations" ] ] ] 7 => array:2 [ "identificador" => "sec0013" "titulo" => "Conclusions" ] 8 => array:2 [ "identificador" => "sec0014" "titulo" => "Funding" ] 9 => array:2 [ "identificador" => "sec0015" "titulo" => "Author contributions" ] 10 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2024-01-26" "fechaAceptado" => "2024-03-27" "PalabrasClave" => array:1 [ "en" => array:2 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1842338" "palabras" => array:3 [ 0 => "Metabolic dysfunction-associated fatty liver disease" 1 => "Liver fibrosis" 2 => "Coronary heart disease" ] ] 1 => array:4 [ "clase" => "abr" "titulo" => "Abbreviations" "identificador" => "xpalclavsec1842339" "palabras" => array:9 [ 0 => "MAFLD" 1 => "NAFLD" 2 => "CHD" 3 => "CAP" 4 => "LSM" 5 => "T2DM" 6 => "BMI" 7 => "OR" 8 => "RR" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abss0001" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0002">Introduction and Objectives</span><p id="spara007" class="elsevierStyleSimplePara elsevierViewall">Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at an increased cardiovascular risk. On the contrary, non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with coronary heart disease (CHD). However, it is not known whether patients with significant CHD show a higher frequency of liver fibrosis. This study aimed to determine the frequency of MASLD and liver fibrosis in patients with CHD and to assess whether coronary stenosis is significantly associated with MASLD and fibrosis.</p></span> <span id="abss0002" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0003">Patients and Methods</span><p id="spara008" class="elsevierStyleSimplePara elsevierViewall">This observational and analytical study included adult patients without any known liver disease who underwent coronary angiography for suspected coronary artery disease (Jul 2021–Jul 2022). The presence of significant CHD (> 50% stenosis of at least one coronary artery) was determined. Liver elastography (FibroScan®) was performed up to 6 months after the coronary angiographic study to determine liver fibrosis, a measurement of liver stiffness (> 6.5 Kpa). Fisher's test, Mann–Whitney U test, and logistic regression models were used (<span class="elsevierStyleItalic">p</span> < 0.05).</p></span> <span id="abss0003" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0004">Results</span><p id="spara009" class="elsevierStyleSimplePara elsevierViewall">The study included 113 patients (76% men, average age: 63 years [standard deviation: 9.9]), of which 72% presented with significant CHD. The prevalence rate of MASLD was 52%. Liver fibrosis was present in 12% of the patients and all patients in the significant CHD group (<span class="elsevierStyleItalic">p</span> = 0.007). An increase in the number of vessels with significant CHD increased the probability of liver fibrosis (odds ratio, 1.79; 95% confidence interval, 1.06–3.04; <span class="elsevierStyleItalic">p</span> = 0.029).</p></span> <span id="abss0004" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0005">Conclusions</span><p id="spara010" class="elsevierStyleSimplePara elsevierViewall">MASLD is highly prevalent in patients with significant CHD but without known liver damage. These data suggest that MASLD and liver fibrosis should be investigated in patients with CHD. The presence of confounding variables, especially the presence of type 2 diabetes mellitus, should be evaluated in further studies.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abss0001" "titulo" => "Introduction and Objectives" ] 1 => array:2 [ "identificador" => "abss0002" "titulo" => "Patients and Methods" ] 2 => array:2 [ "identificador" => "abss0003" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abss0004" "titulo" => "Conclusions" ] ] ] ] "multimedia" => array:4 [ 0 => array:8 [ "identificador" => "fig0001" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1900 "Ancho" => 2167 "Tamanyo" => 152538 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0001" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spara001" class="elsevierStyleSimplePara elsevierViewall">Relationship between the number of coronary arteries with significant stenosis and the presence of hepatic fibrosis.</p>" ] ] 1 => array:8 [ "identificador" => "tbl0001" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0002" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spara003" class="elsevierStyleSimplePara elsevierViewall">SD, standard deviation; BMI, body mass index; IQR, interquartile range; GOT, glutamic oxaloacetic transaminase; LDL, low-density lipoprotein.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><a name="en0001"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><a name="en0002"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black">With coronary heart disease (<span class="elsevierStyleItalic">n</span> = 81) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><a name="en0003"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black">Without coronary heart disease (<span class="elsevierStyleItalic">n</span> = 32) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><a name="en0004"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black">P value \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><a name="en0005"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleBold">Age in years</span>, media (SD) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0006"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">63.6 (9.9) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0007"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">62.3 (11.2) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0008"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.254 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0009"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleBold">Male gender</span>, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0010"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">67 (83 %) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0011"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">19 (59) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0012"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.008 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0013"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleBold">Comorbidities</span>, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0014"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0015"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0016"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0017"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Hypertension \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0018"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">63 (78) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0019"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">22 (69) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0020"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.316 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0021"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Diabetes Mellitus 2 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0022"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">35 (43) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0023"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">7 (22) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0024"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.034 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0025"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Dyslipidemia \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0026"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">49 (60) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0027"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">16 (50) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0028"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.309 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0029"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleBold">Alcohol consumption</span> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0030"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">3 (4 %) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0031"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">4 (13 %) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0032"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.081 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0033"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleBold">Anthropometry</span>, median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0034"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0035"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0036"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0037"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>BMI \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0038"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">28.7 (24.9 – 30.1) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0039"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">27.2 (26.1 – 29.5) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0040"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.589 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0041"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Waist circumference \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0042"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">99.5 (92 – 106) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0043"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">98.5 (89 – 105) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0044"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.515 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0045"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleBold">Laboratory</span>, median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0046"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0047"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0048"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0049"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Glycemia \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0050"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">109 (94 – 138) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0051"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">102 (96 – 112) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0052"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.173 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0053"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Cholesterol \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0054"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">145 (112 – 191) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0055"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">157 (137 – 181) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0056"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.226 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0057"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Triglycerides \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0058"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">143 (110 – 222) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0059"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">117 (86 – 208) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0060"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.226 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0061"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Bilirubin \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0062"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.57 (0.47 – 0.74) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0063"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.55 (0.43 – 0.83) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0064"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.512 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0065"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Alkaline phosphatases \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0066"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">86 (72 – 101) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0067"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">81 (68 – 94) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0068"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.218 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0069"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>GOT \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0070"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">35 (28 – 40) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0071"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">27 (24 – 35) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0072"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.021 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0073"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>LDL \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0074"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">84 (54 – 121) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0075"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">71 (30 – 84) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0076"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.165 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3578878.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spara002" class="elsevierStyleSimplePara elsevierViewall">Demographic and clinical characteristics of the sample and their association with coronary heart disease.</p>" ] ] 2 => array:8 [ "identificador" => "tbl0002" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0003" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spara005" class="elsevierStyleSimplePara elsevierViewall">CAP, controlled attenuation parameter.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><a name="en0077"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><a name="en0078"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black">With coronary heart disease (<span class="elsevierStyleItalic">n</span> = 81) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><a name="en0079"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black">Without coronary heart disease (<span class="elsevierStyleItalic">n</span> = 32) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><a name="en0080"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black">P value \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><a name="en0081"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleBold"><span class="elsevierStyleUnderline">Steatosis</span></span> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0082"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0083"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0084"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0085"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleBold">CAP</span>, median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0086"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">251 (222 – 297) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0087"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">255 (220 – 301) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0088"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.631 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0089"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleBold">Steatosis</span>, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0090"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0091"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0092"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0093"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>No steatosis \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0094"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">40 (49) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0095"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">14 (44) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0096"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="4" align="left" valign="top">0.598</td></tr><tr title="table-row"><a name="en0097"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Mild (S1) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0098"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">9 (11) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0099"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">6 (19) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0101"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Moderate (S2) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0102"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">6 (7) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0103"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">1 (3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0105"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Severe (S3) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0106"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">26 (32) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0107"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">11 (34) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0109"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleBold"><span class="elsevierStyleUnderline">Fibrosis</span></span> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0110"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0111"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0112"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0113"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleBold">kPa ≥ 6,5</span>, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0114"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">14 (17) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0115"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0 (0) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0116"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.007 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0117"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleBold">kPa</span>, median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0118"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">4.5 (4.1 – 6) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0119"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">4.5 (4.0 – 5.1) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0120"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.292 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0121"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleBold">Fibrosis stage</span>, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0122"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0123"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0124"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0125"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>F0 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0126"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">64 (79) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0127"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">30 (94) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0128"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="5" align="left" valign="top">0.601</td></tr><tr title="table-row"><a name="en0129"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>F1 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0130"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">9 (11) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0131"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">2 (6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0133"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>F2 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0134"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">3 (4) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0135"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0 (0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0137"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>F3 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0138"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">3 (4) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0139"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0 (0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0141"></a><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>F4 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0142"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">2 (2) \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0143"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0 (0) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3578879.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spara004" class="elsevierStyleSimplePara elsevierViewall">Steatosis and fibrosis measured by hepatic elastography and its relationship with coronary heart disease.</p>" ] ] 3 => array:8 [ "identificador" => "tbl0003" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0004" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><a name="en0145"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black">Model \t\t\t\t\t\t\n \t\t\t\t\t\t</th><a name="en0146"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black">Odds Ratio \t\t\t\t\t\t\n \t\t\t\t\t\t</th><a name="en0147"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black">Confidence interval 95 % \t\t\t\t\t\t\n \t\t\t\t\t\t</th><a name="en0148"></a><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="top" scope="col" style="border-bottom: 2px solid black">P value \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><a name="en0149"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleItalic">Nº of vessels affected</span> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0150"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0151"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0152"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0153"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleBold">Model 1</span> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0154"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0155"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0156"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0157"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Nº of vessels affected \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0158"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">1.80 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0159"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">1.06 – 3.04 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0160"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.029 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0161"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleBold">Model 2</span> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0162"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0163"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0164"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0165"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Nº of vessels affected \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0166"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">1.55 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0167"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.88 – 2.75 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0168"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.132 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0169"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Type 2 Diabetes Mellitus \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0170"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">6.59 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0171"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">1.67 – 25.93 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0172"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.007 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0173"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleBold">Model 3</span> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0174"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0175"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0176"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0177"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Nº of vessels affected \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0178"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">1.94 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0179"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">1.12 – 3.36 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0180"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.018 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0181"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Obesity \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0182"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">2.33 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0183"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.66 – 8.22 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0184"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.187 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0185"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleItalic">≥ 2 vessels affected</span> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0186"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0187"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0188"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0189"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleBold">Model 1</span> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0190"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0191"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0192"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0193"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>≥ 2 vessels affected \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0194"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">3.44 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0195"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">1.07 – 11.08 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0196"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.038 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0197"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleBold">Model 2</span> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0198"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0199"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0200"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0201"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>≥ 2 vessels affected \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0202"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">2.28 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0203"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.66 – 7.87 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0204"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.192 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0205"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Type 2 Diabetes Mellitus \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0206"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">6.64 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0207"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">1.67 – 26.27 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0208"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.007 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0209"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleBold">Model 3</span> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0210"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0211"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0212"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0213"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>≥ 2 vessels affected \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0214"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">4.26 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0215"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">1.26 – 14.41 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0216"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.020 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><a name="en0217"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top"><span class="elsevierStyleHsp" style=""></span>Obesity \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0218"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">2.51 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0219"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.70 – 8.97 \t\t\t\t\t\t\n \t\t\t\t</td><a name="en0220"></a><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="top">0.154 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3578880.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spara006" class="elsevierStyleSimplePara elsevierViewall">Logistic regression analysis to estimate the risk of hepatic fibrosis according to the number of coronary vessels affected.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "cebibsec1" "bibliografiaReferencia" => array:15 [ 0 => array:3 [ "identificador" => "bib0001" "etiqueta" => "[1]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:11 [ 0 => "Z. Younossi" 1 => "F. Tacke" 2 => "M. Arrese" 3 => "B. Chander Sharma" 4 => "I. Mostafa" 5 => "E. Bugianesi" 6 => "V. Wai-Sun Wong" 7 => "Y. Yilmaz" 8 => "J. George" 9 => "J. Fan" 10 => "M.B Vos" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.30251" "Revista" => array:7 [ "tituloSerie" => "Hepatology" "fecha" => "2019" "volumen" => "69" "numero" => "6" "paginaInicial" => "2672" "paginaFinal" => "2682" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30179269" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0002" "etiqueta" => "[2]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:16 [ 0 => "A. Riquelme" 1 => "M. Arrese" 2 => "A. Soza" 3 => "A. Morales" 4 => "R. Baudrand" 5 => "R.M. Pérez-Ayuso" 6 => "R. González" 7 => "M. Alvarez" 8 => "V. Hernández" 9 => "M.J. García-Zattera" 10 => "F. Otarola" 11 => "B. Medina" 12 => "A. Rigotti" 13 => "J.F. Miquel" 14 => "G. Marshall" 15 => "F. Nervi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1478-3231.2008.01823.x" "Revista" => array:7 [ "tituloSerie" => "Liver Int" "fecha" => "2009" "volumen" => "29" "numero" => "1" "paginaInicial" => "82" "paginaFinal" => "88" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19207970" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0003" "etiqueta" => "[3]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Increasing frequency of obesity in Chile" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "F. Vio" 1 => "J. Kain" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4067/s0034-98872019000901114" "Revista" => array:7 [ "tituloSerie" => "Rev Med Chil" "fecha" => "2019" "volumen" => "147" "numero" => "9" "paginaInicial" => "1114" "paginaFinal" => "1121" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33625444" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0004" "etiqueta" => "[4]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:9 [ 0 => "N. Motamed" 1 => "B. Rabiee" 2 => "H. Poustchi" 3 => "B. Dehestani" 4 => "G.R. Hemasi" 5 => "M.R. Khonsari" 6 => "M. Maadi" 7 => "F.S. Saeedian" 8 => "F. Zamani" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clinre.2016.07.005" "Revista" => array:7 [ "tituloSerie" => "Clin Res Hepatol Gastroenterol" "fecha" => "2017" "volumen" => "41" "numero" => "1" "paginaInicial" => "31" "paginaFinal" => "38" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27597641" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0005" "etiqueta" => "[5]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association between liver fibrosis and coronary heart disease risk in patients with non-alcoholic fatty liver disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:10 [ 0 => "S. Dogan" 1 => "M. Celikbilek" 2 => "Y.K. Yilmaz" 3 => "S. Sarikaya" 4 => "G. Zararsiz" 5 => "H.I. Serin" 6 => "E. Borekci" 7 => "L. Akyol" 8 => "I. Pirti" 9 => "S.E. Davarci" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MEG.0000000000000286" "Revista" => array:7 [ "tituloSerie" => "Eur J Gastroenterol Hepatol" "fecha" => "2015" "volumen" => "27" "numero" => "3" "paginaInicial" => "298" "paginaFinal" => "304" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25629574" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0006" "etiqueta" => "[6]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "G. argher" 1 => "C.D. Byrne" 2 => "A. Lonardo" 3 => "G. Zoppini" 4 => "C. Barbui" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2016.05.013" "Revista" => array:7 [ "tituloSerie" => "J Hepatol" "fecha" => "2016" "volumen" => "65" "numero" => "3" "paginaInicial" => "589" "paginaFinal" => "600" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27212244" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0007" "etiqueta" => "[7]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S. Wu" 1 => "F. Wu" 2 => "Y. Ding" 3 => "J. Hou" 4 => "J. Bi" 5 => "Z. Zhang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/srep33386" "Revista" => array:5 [ "tituloSerie" => "Sci Rep." "fecha" => "2016" "volumen" => "6" "paginaInicial" => "33386" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27633274" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0008" "etiqueta" => "[8]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Non-alcoholic fatty liver disease, liver fibrosis and cardiovascular disease in the adult US population" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S. Ciardullo" 1 => "R. Cannistraci" 2 => "S. Mazzetti" 3 => "A. Mortara" 4 => "G. Perseghin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fendo.2021.711484" "Revista" => array:4 [ "tituloSerie" => "Front Endocrinol (Lausanne)" "fecha" => "2021" "volumen" => "12" "itemHostRev" => array:3 [ "pii" => "S014067361261085X" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0009" "etiqueta" => "[9]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: the framingham heart study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:8 [ 0 => "M.T. Long" 1 => "X. Zhang" 2 => "H. Xu" 3 => "C.T. Liu" 4 => "K.E. Corey" 5 => "R.T. Chung" 6 => "R. Loomba" 7 => "E.J. Benjamin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.31608" "Revista" => array:7 [ "tituloSerie" => "Hepatology" "fecha" => "2021" "volumen" => "73" "numero" => "2" "paginaInicial" => "548" "paginaFinal" => "559" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33125745" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0010" "etiqueta" => "[10]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Non-alcoholic fatty liver disease is associated with coronary artery disease in Koreans" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:12 [ 0 => "D.H. Choi" 1 => "S.J. Lee" 2 => "C.D. Kang" 3 => "M.O. Park" 4 => "D.W. Choi" 5 => "T.S. Kim" 6 => "W. Lee" 7 => "B.R. Cho" 8 => "Y.H. Kim" 9 => "B.K. Lee" 10 => "D.R. Ryu" 11 => "J.W. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3748/wjg.v19.i38.6453" "Revista" => array:7 [ "tituloSerie" => "World J Gastroenterol" "fecha" => "2013" "volumen" => "19" "numero" => "38" "paginaInicial" => "6453" "paginaFinal" => "6457" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24151364" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0011" "etiqueta" => "[11]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bypass Angioplasty Revascularization Investigation (BARI): baseline clinical and angiographic data" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:10 [ 0 => "W.J. Rogers" 1 => "E.L. Alderman" 2 => "B.R. Chaitman" 3 => "G. DiSciascio" 4 => "M. Horan" 5 => "B. Lytle" 6 => "M.B. Mock" 7 => "A.D. Rosen" 8 => "K. Sutton-Tyrrell" 9 => "B.H. Weiner" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Cardiol" "fecha" => "1995" "volumen" => "75" "numero" => "9" "paginaInicial" => "9C" "paginaFinal" => "17C" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0012" "etiqueta" => "[12]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with non-alcoholic fatty liver disease" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "NASH Clinical Research Network" "etal" => false "autores" => array:15 [ 0 => "M.S. Siddiqui" 1 => "R. Vuppalanchi" 2 => "M.L. Van Natta" 3 => "E. Hallinan" 4 => "K.V. Kowdley" 5 => "M. Abdelmalek" 6 => "B.A. Neuschwander-Tetri" 7 => "R. Loomba" 8 => "S. Dasarathy" 9 => "D. Brandman" 10 => "E. Doo" 11 => "J.A. Tonascia" 12 => "D.E. Kleiner" 13 => "N. Chalasani" 14 => "A.J. Sanyal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cgh.2018.04.043" "Revista" => array:7 [ "tituloSerie" => "Clin Gastroenterol Hepatol" "fecha" => "2019" "volumen" => "17" "numero" => "1" "paginaInicial" => "156" "paginaFinal" => "163" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29705261" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0013" "etiqueta" => "[13]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S. Leoni" 1 => "F. Tovoli" 2 => "L. Napoli" 3 => "I. Serio" 4 => "S. Ferri" 5 => "L. Bolondi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3748/wjg.v24.i30.3361" "Revista" => array:7 [ "tituloSerie" => "World J Gastroenterol" "fecha" => "2018" "volumen" => "24" "numero" => "30" "paginaInicial" => "3361" "paginaFinal" => "3373" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30122876" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0014" "etiqueta" => "[14]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: a meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:12 [ 0 => "W. Wen" 1 => "H. Li" 2 => "C. Wang" 3 => "C. Chen" 4 => "J. Tang" 5 => "M. Zhou" 6 => "X. Hong" 7 => "Y. Cheng" 8 => "Q. Wu" 9 => "X. Zhang" 10 => "Z. Feng" 11 => "M. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fendo.2022.934225" "Revista" => array:3 [ "tituloSerie" => "Front Endocrinol (Lausanne)" "fecha" => "2022" "volumen" => "13" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0015" "etiqueta" => "[15]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:19 [ 0 => "R. Lomonaco" 1 => "E. Godinez Leiva" 2 => "F. Bril" 3 => "S. Shrestha" 4 => "L. Mansour" 5 => "J. Budd" 6 => "J. Portillo Romero" 7 => "S. Schmidt" 8 => "K.L. Chang" 9 => "G. Samraj" 10 => "J. Malaty" 11 => "K. Huber" 12 => "P. Bedossa" 13 => "S. Kalavalapalli" 14 => "J. Marte" 15 => "D. Barb" 16 => "D. Poulton" 17 => "N. Fanous" 18 => "K Cusi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dc20-1997" "Revista" => array:7 [ "tituloSerie" => "Diabetes Care" "fecha" => "2021" "volumen" => "44" "numero" => "2" "paginaInicial" => "399" "paginaFinal" => "406" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33355256" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/16652681/0000002900000004/v1_202406280659/S1665268124003053/v1_202406280659/en/main.assets" "Apartado" => array:4 [ "identificador" => "78265" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original Articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/16652681/0000002900000004/v1_202406280659/S1665268124003053/v1_202406280659/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268124003053?idApp=UINPBA00004N" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 5 | 0 | 5 |
2024 October | 27 | 3 | 30 |
2024 September | 31 | 10 | 41 |
2024 August | 45 | 8 | 53 |
2024 July | 45 | 22 | 67 |
2024 June | 59 | 29 | 88 |
2024 May | 76 | 28 | 104 |